Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (October 2024)
20 slides from Bio-gene Technology's investor presentation, Oct 2, 2024
Slide 1: ASX Release: Investor Presentation
BIO-GENE ASX RELEASE TECHNOLOGY LTD 2 October 2024 Investor Presentation Bio-Gene Technology Limited (ASX: BGT, ‘Bio-Gene’ or the ‘Company’), an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance, is pleased to provide an updated non-confi
Slide 2: Investor Presentation
Bio-Gene Technology Limited | ASX: BGT Investor Presentation Developing new insecticides derived from nature to achieve high impact worldwide. October 2024 www.bio-gene.com.au www.bio-gene.com.au 1
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an
Slide 4: Contents
Contents Investment Highlights 04. Market Overview 06. Product Overview 08. Commercial Strategy 09. Key Metrics & Milestones 14. www.bio-gene.com.au www.bio-gene.com.au 3
Slide 5: Investment Highlights
Investment Highlights Focused development of two new insecticides with strong commercial validation. 01. Two New Actives Late-stage development: two insecticidal compounds derived from nature with novel modes of action: » Flavocide® and Qcide® are derived from a unique sub-type of eucalypt » effecti
Slide 6: Experienced Board of Directors & Management Team
Experienced Board of Directors & Management Team A team with strong experience in product development, partnering and commercialisation. Alex Ding Andrew Guthrie Tim Grogan Edmond Tern Chairman Non-Executive Director MD & CEO CFO & Company Secretary Previously partner at two law firms and 32 years’
Slide 7: The Global Challenges We Help Solve
The Global Challenges We Help Solve Our products address the demand for effective pest control & sustainable agriculture. Public Health Vector Control Crop Protection The mosquito is “the world’s deadliest animal”1 Pesticides are critical to farming » Causes more human deaths than any other creature
Slide 8: The Global Challenges We Help Solve
The Global Challenges We Help Solve Meeting the increasing market demands for safe and effective pest control solutions and new modes of action. A diminishing pool of available products for farmers and public health officials: » Insects’ resistance to insecticides » Loss of approved registrations fo
Slide 9: Our Unique Products Derived from Nature
Our Unique Products Derived from Nature Qcide® Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (Gypmie messmate) currently farmed in northern Australia. ✓ 12th harvest in QLD completed in 2024 Flavocide® Flavocide is based on flavesone, a naturally occurring
Slide 10: Flavocide & Qcide - Multiple Market Segments
Flavocide & Qcide - Multiple Market Segments Bio-Gene is targeting five large well-developed global markets Sectors Crop Protection Grain Storage Public Health Consumer Applications Animal Health Urban Pest Management, Vector Control for Malaria, Livestock & Pet-care Food & Fibre Stored Grain Oils,
Slide 11: Flavocide & Qcide - Multiple Market Segments
Flavocide & Qcide - Multiple Market Segments Bio-Gene is targeting five large well-developed global markets Active constituent Description Sectors Target uses Partners & Collaborators 1 Grain Protectant Crop protection Admixture to grain 2 Outdoor Space Spray Public health Flying insects Flavocide 3
Slide 12: Flavocide Development Path
Flavocide Development Path Regulatory approval of a formulated product is a two-step process. Commercial Partner Agreements Launch Regulatory Development (market) Manufacturing process improvements and scale-up #1. Flavocide AI: data and regulatory dossier 1st dossier evaluation by APVMA Formulation
Slide 13: Multiple Commercial Partnerships in Place
Multiple Commercial Partnerships in Place Bio-Gene has established commercial partnerships with global partners, with additional commercial partners in progress. Applies advanced botanical science to the Clarke is the largest vertically integrated Evergreen is a market leader in consumer development
Slide 14: Key Collaborations Snapshot
Key Collaborations Snapshot R&D partnerships advance development and registration of Qcide and Flavocide. Envu was founded in 2022 from Bayer’s environmental science division. Envu’s product pipeline focuses on novel, safe and environmentally- friendly insecticides » Evaluating Flavocide as a commer
Slide 15: Capital Structure
Capital Structure 12-Month Share Price Performance 0.09 0.9 Key metrics (26 September 2024) Millions 0.08 0.8 0.07 0.7 ASX code BGT 0.06 0.6 Share price $0.045 0.05 0.5 0.04 0.4 Market Capitalisation ~A$9m 0.03 0.3 0.02 0.2 Shares on issue 201,361,570 0.01 0.1 Cash (30 June 2024) A$2.21m 0 0 10/23 1
Slide 16: Recent Milestones & News flow
Recent Milestones & News flow 8 August 2024 14 August 2024 2 September 2024 Study plans for Flavocide on track Envu collaboration to evaluate Flavocide Flavocide production successful at following APVMA feedback for mosquito management pre-commercial scale www.bio-gene.com.au www.bio-gene.com.au 15
Slide 17: Bio-Gene's Strategic Priorities
Bio-Gene’s Strategic Priorities Strategy is focused on efficient development and approval of Flavocide and Qcide, with more commercial partnerships. Speed Efficient Use of Capital Particularly the pre-registration To leverage the funding from manufacturing and safety shareholders wherever possible s
Slide 18: Key Forward Milestones & News Flow
Key Forward Milestones & News Flow Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow. 01 02 03 Flavocide & Qcide development Partnering & commercial Funding & other support ✓ Flavocide regulatory studies ✓ New commercial partnerships ✓
Slide 19: Investment highlights
Investment highlights Bio-Gene is targeting five large well-developed global markets Bio-Gene is developing two naturally derived insecticidal active ingredients, overcoming resistance by controlling pests via a novel mode of action High margin business model with significant operating leverage Subs
Slide 20: Contact
Contact Tim Grogan Managing Director & CEO timg@bio-gene.com.au Matthew Wright NWR Communications matt@nwrcommunications.com.au 0451 896 420 www.bio-gene.com.au www.bio-gene.com.au 19
Bio-gene Technology — Investor Presentation (October 2024) on 6ix